Chen Yu

About

Dr. Yu is the founder and Managing Partner at TCGX. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has led investments or served on the board of over a dozen private/public companies, including Abivax (NASDAQ:ABVX) Upstream Bio (NASDAQ:UPB), Carmot (acquired by Roche), Structure Therapeutics (NASDAQ:GPCR), AdaRx, Alkeus, Aviceda, Arbor Biotechnologies, Tarsus Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi-I-Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Nabriva (NASDAQ: NBRV), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), and NKF Pharma (SHA: 603707). While at Vivo,

Source (opens in a new tab)